The Covid-19 Pandemic
The Covid-19 pandemic has created an immediate worldwide need for low-cost consumer health self-monitoring technologies. As with any infection, one of the early signs of illness is the onset of a fever. Ideally, fever monitoring is done by patients at-home using their phones.
Gentag, Inc. and its patent holding company, Altivera, LLC, are experienced in the area of wireless self-monitoring technologies, having predicted the Near Field Communication (NFC) consumer diagnostics cell phone markets in 2003.
GENTAG / ALTIVERA COVID-19 Screening Technologies and Intellectual Property
Gentag has worldwide patents in several key areas related to the virus. These patented technologies cover the consumer self-diagnostic health markets with cell phones. Specifically the patented Gentag/Altivera technologies related to Covid-19 include the following:
- NFC / Bluetooth fever patches (licensed)
- Optical fever patches
RAPID DIAGNOSTIC TESTS
- NFC / Bluetooth lateral flow immunoassays
- Optical rapid tests
ADVANCED DIAGNOSTIC TESTS
- NFC / Bluetooth Lab-on-a-Chip
- NFC / Bluetooth biomarker diagnostic skin patches
- Biologic/biosimilar drug compliance monitoring platform
- Drug authentication platform
The Gentag/Altivera IP offers a unifying patented platform for the Covid-19 markets, as well as future markets for consumer health self-monitoring using cell phones.